I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasma cell | 8 studies | 32% ± 11% | |
| ciliated cell | 8 studies | 32% ± 11% | |
| natural killer cell | 7 studies | 22% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 7 studies | 20% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 5 studies | 20% ± 1% | |
| CD8-positive, alpha-beta T cell | 5 studies | 23% ± 10% | |
| endothelial cell | 5 studies | 26% ± 6% | |
| epithelial cell | 5 studies | 35% ± 14% | |
| plasmablast | 4 studies | 33% ± 22% | |
| basal cell | 4 studies | 28% ± 11% | |
| mast cell | 3 studies | 19% ± 1% | |
| deuterosomal cell | 3 studies | 19% ± 4% | |
| CD4-positive, alpha-beta T cell | 3 studies | 27% ± 12% | |
| smooth muscle cell | 3 studies | 18% ± 1% | |
| fibroblast | 3 studies | 24% ± 7% | |
| gamma-delta T cell | 3 studies | 27% ± 14% |
